Providing a stable supply of high-quality pharmaceuticals and other products is an important duty of a pharmaceutical company.

We will strengthen our quality assurance and production systems to ensure uninterrupted access to reliable pharmaceuticals and other products for patients and medical institutions. 

We are also fully committed to managing risks associated with raw material procurement and taking preventive action against such risks.

• Manufacture and stably supply pharmaceuticals and other products of guaranteed quality by maintaining the quality management system compliant with global standards.
• Ensure a continuous supply of pharmaceuticals and other products through rigorous management of associated with raw material procurement and product supply.

1. Engage in continuous GMP compliance activities (compliance with the GMP Ministerial Ordinance, manufacturing and marketing approval matters).  
2. Foster a quality culture to ensure a stable supply of pharmaceuticals and other products of guaranteed quality.
3. Enhance optimal inventory control of raw materials and products as well as preventive maintenance activities aimed at uninterrupted production.

• Conducted 20 audits (paper and on-site) of contract manufacturers, suppliers,　and distributors 
• Conducted GQP self-inspections, QMS business inspections, and conformity verification of manufacturers and distributors
• Improved and enhanced quality awareness by providing compliance education concerning the Quality Management System Regulation and other regulations, conducting quality awareness surveys in plants, and providing education to foster a quality culture
• Founded the Monozukuri Academy, a department responsible for personnel development at the Takahagi Plant
• Proceeded with implementation of a computerized maintenance management system to enhance preventive maintenance of facilities

• Progress with management reviews
• Progress with audits and audit responses
• Progress with fostering a quality culture
• Status of inventory availability based on production schedules
• Status of maintenance for quality assurance and stable production
• Progress with maintaining manuals to prepare against large-scale disasters

Enabling greater numbers of patients over a wider area to appropriately use pharmaceuticals and other products that address unmet medical needs is the mission of a pharmaceutical company. 

It is a mission of a pharmaceutical company to promote responsible use of pharmaceuticals and other products that address unmet medical needs to a greater number of patients. 

We are forging ahead with global expansion of pharmaceuticals and other products meeting medical needs. As a pharmaceutical manufacturer, we also strive to enhance information provision to expand appropriate recognition of the safety and efficacy of our pharmaceuticals and medical devices and of the diseases that our products treat.

• Provide pharmaceuticals and medical devices with high efficacy and safety to a greater number of patients.
• Appropriately provide information about the safety and efficacy of pharmaceuticals and medical devices as well as promoting their proper use.

1. Cooperate with sales partners to raise market awareness of existing products.
2. Accelerate global expansion of existing products and products in development.
3. Upgrade products in line with medical needs.
4.  Provide information of high medical and scientific value that contributes to post-marketing product development.
5. Enhance operation of disease awareness websites and informationprovision to the media.
6. We contribute to the advancement of glycoscience by providing information through our Glycoforum website.
7. Comply with post-marketing safety management standards, and gather, evaluate, and provide safety management information promptly and properly.

• Implemented awareness improvement measures in Japan and overseas
• Commenced sales of MucoUp in China
• Changed distributors to strengthen and promote sales in Italy
• Promoted evidence generation and academic communication, which contribute to post-marketing drug development (six academic paper submissions, five academic presentations) 
• Enhanced information posted on disease awareness and sales websites
• Continued disseminating carbohydrate-related information on Glycoforum (year-on-year increase in traffic) 
• Implemented company-wide disclosure and appropriate provision of safety information and internal safety information education

• Number of products shipped (pharmaceuticals and medical devices)
• Status of product improvement 
• Activities for providing information to improve product value 
• Number of views for disease awareness websites
• Hosting of media seminars, etc.
• Progress with educating about pharmacovigilance

Compliance is the foundation of corporate activities. Furthermore, pharmaceutical companies are required to have a higher sense of ethics and must comply with pharmaceutical industry guidelines and standards.

Seikagaku is managed to ensure that each individual employee not only complies with laws and regulations but also acts with high ethical standards. 

Additionally, business operations meeting society’s expectations are essential for sustainable corporate growth and enhancement in corporate value over the medium and long term. We are continuously working to develop a highly effective corporate governance system.

• All directors, officers, and employees follow the compliance program and act with strong compliance awareness.
• Develop an optimal corporate governance system in order to engage in decision making that is transparent and fair as well as quick and decisive.

1. Foster compliance awareness by periodically providing education about the Compliance Code of Conduct and other compliance related matters.
2. Establish internal and external consultation/whistleblowing channels and appropriately respond to any issues raised. 
3. We will conduct appropriate product promotion and information provision activities.
4. Monitor the status of corporate governance by the Board and review the corporate governance system periodically.
5. Enhance provision of information to Outside Directors and Outside Audit & Supervisory Board Members; promote improvement activities based on the results of the effectiveness evaluations of the Board.

• Conducted roundtable discussion-style compliance training on the theme “Let’s do the right thing” 
• Conducted code of conduct training and awareness surveys (once annually) to foster an awareness of compliance
• Conducted internal audits to check compliance with anti-corruption and anti-bribery measures
• Assessed promotional materials and monitored information provision activities in order to engage in appropriate product promotion and information provision activities
• Conducted 21 in-house education and training sessions pertaining to the Promotion Code, the Fair Competition Code, Ministry of Health, Labor and Welfare notifications, and other topics
• Began an initiative to elicit views and issues from outside directors and outside Audit & Supervisory Board members with the aim of improving Board of Directors effectiveness

• Progress with compliance education
• Usage of whistleblowing channel consultation and reporting desks
• Operational status of internal control systems
• Corporate Governance Code compliance 
• Information provision to outside directors
• Evaluations of the effectiveness of the Board of Directors and improvements activities

• Appropriate response to the Corporate Governance Code
• Evaluations of the effectiveness of the Board of Directors by all Board members and auditors, and its verification by outside directors

►Annual evaluation and verification

Results (Fiscal 2025)

• Maintained proper running of Board and other meetings as well as the internal control system for various committees
• In addition to the annual effectiveness evaluation and verification, continuously solicit feedback and identify issues from outside directors following Board of Directors meetings

The foundation for corporate growth is human resource management that secures and develops diverse human resources who prove valuable in business activities and that promotes their advancement.

We consider human resources to be an important corporate asset and develop human resources capable of creating new value. 

We are also supporting all employees with the environment, systems, and frameworks where they can fully demonstrate their capabilities, in order that their advancement becomes the driving force for our sustainable growth.

• Develop and retain autonomous employees who are able to achieve results proactively with a sense of passion and pride while improving their skills and building their careers.

1. We will etablish our organization’s uniqueness and competitive advantage by strategically recruiting and placing a diverse workforce, ensuring that the power of diversity unlocks the full potential of every individual.
2. To nurture talent with curiosity and a spirit of inquiry who autonomously continue to learn and grow, we provide systematic and challenging learning opportunities and career development programs.
3. We foster an open and autonomous organizational culture that encourages taking on challenges to create new value beyond existing frameworks, while respecting diverse opinions and promoting collaboration and co-creation.
4. We maximize employee engagement by providing opportunities to realize how their work contributes to society and their own career growth, and by fairly evaluating and rewarding their achievements.
5. We prioritize the physical and mental well-being of our employees and promote initiatives that support long-term career continuity regardless of life events.

• Promoted human resource utilization by introducing a new personnel management system and gathering employee career and skills information
• Introduced the Region-Specific Employment System as part diversity and inclusion promotion. It offers peace of mind knowing that the worksite will be rooted in people’s local community
• Conducted internal recruitment for the purpose of effective personnel allocation
• Introduced 360 surveys and strengthened development of management-level personnel
• Conducted an employee engagement survey (once annually)
• Provided remedial care in light of annual stress check results as an employee health promotion activity
• Promoted company-wide overtime work reduction to improve work-life balance (overtime work: 12.2% reduction year on year) 

• Changes to HR systems
• Percentages of women hired/currently employed
• Serving in managerial positions
• Percentages of mid-career employees hired/currently employed/serving in managerial positions
• Percentage of persons with disabilities hired
• Attrition rate (voluntary)
• Three-year retention rate of new graduate recruits
• Status of education and training for human resource development
• Status of work style reforms and initiatives to improve work-life balance
• Average number of days of paid leave taken
• Average monthly overtime hours number of overtime hours per month
• Number of employees taking childcare and nursing care leave (men and women, including contract employees) 
• Percentage of workers returning to work after childcare leave
• Implementation status of mental health care measures, etc.

• Employee engagement survey 
  ►Overall Satisfaction
• Number of career training courses
  ►Targeting 15 or more per year

The impacts of global warming and other environmental problems are apparent, and measures to protect the environment and preserve biodiversity have become a top priority for society. 
Responding to these problems is one of the business challenges that relates not only to risk reduction but also to profit opportunities.

As a member of society, we aim to maintain a balance between environmental protection and business growth and engage in business activities with a low environmental footprint, on top of complying with environmental laws and regulations.

• Contribute to the realization of a sustainable society by implementing measures for reducing environmental impact and climate change, and preserving biodiversity in our business activities.

1. Implement effective measures for energy use reduction.
2. Convert to energy sources that lead to CO₂ emissions reduction.
3. Mitigate water pollution load by introducing equipment with low environmental impact for water preparation for manufacturing and for wastewater treatment.
4. Undertake biodiversity preservation activities, including a shift to non-animal-based products.

• Achieved continuous reduction in energy use (five-year average energy consumption rate of 98.3% / energy conservation evaluation*2: Class S) 
• Installed high-efficiency equipment and updated air conditioning and facilities 
• Engaged in R&D of fermented GAG, recombinant LAL, and beta-glucan reagents 
• Continued horseshoe crab release and conservation activities at an overseas subsidiary

• Energy use (crude oil equivalent) 
• CO₂ emissions
• Progress with using renewable energy 
• Water pollution load (COD)
• Progress with shift to non-animal origin products 
• Progress with biodiversity preservation activities

• CO₂ emissions (Non-consolidated）
  ►46% reduction by 2030（Scope 1and2 compared to FY2017）
  ►Aim to be carbon neutral by 2050
  ►Scope 3 calculations（disclose figures by 2025）

 
Results (Fiscal 2025)
Scope 1 and 2：8,504 t (67％ reduction compared to FY2017, market-based method)
Scope 3：under calculating